A. Eggermont

Publications879
h-index107
Citations58,701
Highly Influential Citations1,756
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • L. Zitvogel
  • 700 Publications • 96,466 Citations
  • G. Kroemer
  • 1,735 Publications • 255,364 Citations
  • D. Schadendorf
  • 1,281 Publications • 112,235 Citations
  • C. Robert
  • 594 Publications • 91,959 Citations
  • Publications
  • Influence
Final version of 2009 AJCC melanoma staging and classification.
TLDR
Revised melanoma staging system has been made that reflect the improved understanding of this disease and will be formally incorporated into the seventh edition of the AJCC Cancer Staging Manual and implemented by early 2010.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
TLDR
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
TLDR
It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
TLDR
A key role is revealed for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade, which is found to depend on distinct Bacteroides species in mice and patients.
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Answer questions and earn CME/CNE
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
TLDR
The findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a ‘drug holiday’ and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
TLDR
The data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens, and it is surmised that such 'viral mimicry' constitutes a hallmark of successful chemotherapy.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
TLDR
As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence- free survival, overall survival, and distant metastasis-free survival than placebo.
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
...
1
2
3
4
5
...